Tag: biotechnology
In an increasingly hot biotech market, protecting IP is key
John Flavin Contributor More posts by this contributor 2021 should be a banner year for biotech startups that make smart choices early Kevin O’Connor Contributor Kevin A. O’Connor, Ph.D., is a partner in the Intellectual Property practice group at Neal Gerber Eisenberg. After a record year for biotech investment in…
Read More
Cutting out carbon emitters with bioengineering at XTC Global Finals on July 22
Bioengineering may soon provide compelling, low-carbon alternatives in industries where even the best methods produce significant emissions. Utilizing natural and engineered biological process has led to low-carbon textiles from Algiknit, cell-cultured premium meats from Orbillion, and fuels captured from waste emissions via LanzaTech — and leaders from those companies will…
Read More
This startup just created a fast, accurate COVID test that only needs saliva and links to an app
We’re entering a phase in the COVID-19 pandemic where transmission is going to go through the roof because of the Delta variant. But as vaccinations ramp up around the world, the main cost to society now will not be the health services being overwhelmed, but mass disruption to businesses as…
Read More
Extra Crunch roundup: Video pitch decks, Didi’s regulatory struggles, Nothing CEO interview
The numbers don’t lie. According to DocSend, the average pitch deck is reviewed for just three minutes. And if you think a senior VC is studying the presentation your team crafted for months as if it were a Fabergé egg — well, you might be disappointed. Even if you are…
Read More
Biden proposes ARPA-H, a health research agency to ‘end cancer’ modeled after DARPA
In a joint address to Congress last night, President Biden updated the nation on vaccination efforts and outlined his administration’s ambitious goals. Biden’s first 100 days have been characterized by sweeping legislative packages that could lift millions of Americans out of poverty and slow the clock on the climate crisis,…
Read More
2021 should be a banner year for biotech startups that make smart choices early
Michael B. Gray Contributor Michael B. Gray is partner and leader of the private equity, venture capital and growth companies practice, Neal Gerber Eisenberg. John Flavin Contributor Last year was a record 12 months for venture-backed biotech and pharma companies, with deal activity rising to $28.5 billion from $17.8 billion…
Read More